Cipla Limited (CIPLA) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally.

Total Assets Chart for Cipla Limited

Cipla Limited (CIPLA) total assets for FY2026 were INR 425.0B, a 13.7% change from FY2025. Cipla Limited's total assets grew from INR 22.2B in 2004 to INR 425.0B in 2026 (1814.1% over 22 years). Total assets compound annual growth rate: 5-year CAGR of 11.1%, 10-year CAGR of 7.2%, 20-year CAGR of 13.4%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (Indian Rupees)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
₹1.14T
Implied Share Price
₹1406.10
Enterprise Value
₹1.05T
Revenue (TTM)
₹280.68B
EBITDA
₹51.83B
Profit Margin
12.01%
Trailing P/E
34.21
Forward P/E
24.33
Price/Book (MRQ)
3.34
Price/Sales (TTM)
4.05
EV/EBITDA
18.40
EV/Revenue
3.77
Dividend Yield
0.00%
Book Value
₹426.25
Free Cash Flow (FY2026)
₹25.27B
Free Cash Flow Yield
2.22%

Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.